1. Home
  2. TXO vs ACHV Comparison

TXO vs ACHV Comparison

Compare TXO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TXO Partners L.P.

TXO

TXO Partners L.P.

HOLD

Current Price

$14.28

Market Cap

781.2M

Sector

Energy

ML Signal

HOLD

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$7.59

Market Cap

726.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXO
ACHV
Founded
2012
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.2M
726.5M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
TXO
ACHV
Price
$14.28
$7.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $20.50
$14.67
AVG Volume (30 Days)
156.5K
★ 1.4M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
★ 13.57%
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $401,012,000.00
N/A
Revenue This Year
$17.21
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 41.80
N/A
52 Week Low
$10.12
$2.62
52 Week High
$15.58
$8.64

Technical Indicators

Market Signals
Indicator
TXO
ACHV
Relative Strength Index (RSI) 42.70 48.75
Support Level $13.66 $7.01
Resistance Level $14.61 $8.63
Average True Range (ATR) 0.38 0.39
MACD -0.16 -0.04
Stochastic Oscillator 0.00 41.84

Price Performance

Historical Comparison
TXO
ACHV

About TXO TXO Partners L.P.

TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America. Its operations focus on enhancing the development and operation of producing properties through its concentration on efficiency and optimizing exploitation of current wells.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: